All In Biotech

Drug Trial Radar · NCT06254482

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

144

Actual

Start

Aug 25, 2023

Primary completion

Jul 16, 2029

Study completion Jul 16, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.

Conditions

  • Huntington Disease

Interventions

  • VotoplamDrug

    Votoplam will be administered per dose and schedule specified in the arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Month 54
  2. Blood Total Huntingtin Protein (tHTT) LevelsTime frame: Baseline up to Month 52

Locations

24 sites in 10 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Clayton, Australia

  • Novartis Investigative Site

    Westmead, Australia

  • Novartis Investigative Site

    Innsbruck, Austria

  • Novartis Investigative Site

    Ottawa, Canada

  • Novartis Investigative Site

    Angers, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Bologna, Italy

  • Novartis Investigative Site

    Milan, Italy

  • Novartis Investigative Site

    San Giovanni Rotondo, Italy

  • Novartis Investigative Site

    Leiden, Netherlands

  • Novartis Investigative Site

    Christchurch, New Zealand

  • Novartis Investigative Site

    Barakaldo, Spain

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Burgos, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Birmingham, United Kingdom

  • Novartis Investigative Site

    Cardiff, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.